(AOF) – DMS Imaging announces that the transfer of the listing of its shares from the regulated markets Euronext Paris and Brussels (compartment C) to the multilateral trading system Euronext Growth Paris and Brussels will be effective on September 1, 2023. The diagnostic specialist specifies that the request for admission of DMS Imaging shares on the Euronext Growth Paris and Brussels markets was approved by the Euronext Admissions Committee on August 29, 2023. This transfer was authorized by the general meeting of shareholders of the DMS Imaging Group meeting on September 12, 2022.
The transfer will allow DMS Imaging to be listed on a market more appropriate to its size, simplify its operation and reduce its listing costs, while allowing it to continue to benefit from the advantages of a listing on a financial market. . Relaunched in November 2021, this transfer was then intended to “simplify the operation of the company and reduce its costs, while allowing it to continue to benefit from the attractions of the financial markets”.
At the end of the trading session of August 31, 2023, the ordinary shares issued by DMS Imaging will be delisted from the regulated market of Euronext Paris and Brussels and admitted to Euronext Growth Paris and Brussels from September 1, 2023.
AOF – LEARN MORE
Find out more about the specialized distribution sector
Concerns remain
According to the Federation of Specialized Trade, Procos, in October 2022, activity fell by 1.5% over one year. Nevertheless, the beauty and health (+ 5.2%) and specialized food (+ 3.5%) activity is dynamic compared to October 2021. The frequentation of the points of sale was very impacted by the problems of fuel and bad weather. Compared to October 2019, the pre-covid year, the drop in attendance is very sharp (-20.9% in October). Shopping centers and the outskirts are more impacted than city centers with a difference of four to five points.
Several reasons for concern exist for the future. The players are experiencing a very significant scissor effect given the increase in their operating costs while the evolution of demand is very uncertain. Very few brands can pass on the increase in their costs to their selling prices. The federation therefore asks, among other things, to limit the indexation of the Commercial Rent Index to + 3.5% for the rents of all companies in 2023. It also invokes an absolute urgency: to cap the price of energy for 2023 and retroact on the contracts already signed to prevent the rate of failures from accelerating.
Find out more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in financing by venture capital for start-ups. These companies are therefore obliged to carry out redundancy plans. Added to this is a much more restrictive regulatory framework. First, in the United States, the measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of the participants. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemicals) or 13 years (biologicals), with discounts that could range from 35 to 60% for biotechs. Similarly, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.